tiprankstipranks
Advertisement
Advertisement

Diagnos Wins $1M-Plus Federal Backing for Next-Generation Retinal AI Research

Story Highlights
  • Diagnos and ÉTS secured over C$1 million in federal and partner funding to accelerate next-generation AI for retinal image analysis.
  • The multi-year program, co-funded by Diagnos and federal agencies, supports top researchers and strengthens Diagnos’s leadership in clinically focused retinal AI.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.

Claim 55% Off TipRanks

The latest announcement is out from Diagnos ( (TSE:ADK) ).

Diagnos Inc. and Montreal-based engineering school École de technologie supérieure have secured more than C$1 million in federal funding, led by a five-year NSERC Alliance grant and additional Mitacs support, to accelerate development of next-generation AI algorithms for retinal image analysis. The multi-year project, which includes the creation of an industrial research chair at ÉTS and co-funding of C$500,000 from Diagnos, will support eight highly qualified researchers and aims to boost the accuracy and clinical relevance of AI-based retinal disease detection, reinforcing Canada’s research ecosystem and strengthening Diagnos’s positioning as a leader in medical AI for eye health as it moves innovations closer to real-world clinical deployment.

The most recent analyst rating on (TSE:ADK) stock is a Hold with a C$0.29 price target. To see the full list of analyst forecasts on Diagnos stock, see the TSE:ADK Stock Forecast page.

Spark’s Take on TSE:ADK Stock

According to Spark, TipRanks’ AI Analyst, TSE:ADK is a Neutral.

The score is held down primarily by very weak financial performance (large losses, negative equity, and ongoing cash burn). Technicals are comparatively supportive with an uptrend and positive momentum, but valuation is hindered by loss-making results and no dividend data.

To see Spark’s full report on TSE:ADK stock, click here.

More about Diagnos

Diagnos Inc. is a publicly traded Canadian company specializing in the early detection of critical eye-related health problems using artificial intelligence. Its AI-driven retinal image analysis tools are designed to support healthcare clinicians by enhancing diagnostic accuracy, streamlining clinical workflows and improving patient outcomes globally.

Average Trading Volume: 254,130

Technical Sentiment Signal: Sell

Current Market Cap: C$34.92M

Find detailed analytics on ADK stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1